Ticker LaunchIPO · IPHA
Innate Pharma SA
Formerly Innate Pharma, SA
Innate Pharma SA (IPHA) priced its initial public offering on Oct 18, 2019 at $5.50 per ADS, and listed on Nasdaq Global Select. Citigroup was lead-left underwriter, joined by Leerink Partners and Evercore ISI. Cooley and Linklaters advised the company and Davis Polk advised the underwriters.
Innate Pharma SA is a biotechnology company developing first-in-class therapeutic antibodies that harness the immune system against cancer. Its portfolio has an approved product, three clinical candidates and a preclinical pipeline, and it collaborates with companies such as AstraZeneca and Sanofi.
- Status
- IPO
- Ticker
- IPHA
- Exchange
- Nasdaq Global Select
- Priced
- Oct 18, 2019
- IPO price
- $5.50 per ADS
- First filed
- Sep 20, 2019
- Underwriters
- Citigroup, Leerink Partners and Evercore ISI
- Company counsel
- Cooley and Linklaters
- Underwriters' counsel
- Davis Polk
- Sector
- Biotech & pharma
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed Sep 20, 2019
- Latest amendment Oct 4, 2019
- Final prospectus (424B4) Oct 18, 2019
- All filings on EDGAR CIK 1598599
Other Biotech & pharma IPOs in 2019
- Oyster Point Pharma, Inc.OYST · Oct 31, 2019 · $80M
- Phathom Pharmaceuticals, Inc.PHAT · Oct 28, 2019 · $181.7M
- Cabaletta Bio, Inc.CABA · Oct 25, 2019 · $74.8M
- TFF Pharmaceuticals, Inc.TFFP · Oct 25, 2019
- BioNTech SEBNTX · Oct 11, 2019 · $150M
- Vir Biotechnology, Inc.VIR · Oct 11, 2019 · $142.9M